In recent years, global funds are rapidly pouring into the biopharmaceutical industry, driving the sharp rise in the stock prices of pharmaceutical companies, and also driving the continued active investment and financing activities in the BioTCH field
.
In China alone, 89 companies will complete IPOs in the A-share, H-share and U.
S.
stock markets in 2021
.
Since 2022, although the "financing tide" in the pharmaceutical field has slowed down, it has continued.
In the first half of the year, there were 632 investment and financing events in China's medical and health industry, and the disclosed investment and financing amount was 115.
2 billion yuan, of which 583 were investment and financing events in the primary market.
Since then, the investment and financing amount has reached 67.
1 billion yuan
.
It is worth noting that in August, a large number of pharmaceutical companies announced that they had completed financing of 100 million yuan
.
For example, recently, Elite Pharmaceutical Technology (Shanghai) Co.
, Ltd.
(Elite Pharmaceutical Technology lnc.
hereinafter referred to as "Sele Pharmaceutical") announced the completion of nearly 100 million yuan in Series B financing.
It is reported that this round of investment was led by Anhui Chuanggu Capital and Hefei Production The investment capital and Hefei Innovation Investment were jointly completed.
The raised funds will be mainly used to assist the research and development and clinical development of Sele Pharmaceuticals, as well as the construction of new production bases
.
On August 8, Ningbo Haiershi Gene Technology Co.
, Ltd.
(hereinafter referred to as Haiershi Gene) announced that it has received hundreds of millions of yuan in Series C financing
.
It is reported that Heersch Gene, established in 2011, focuses on the two fields of clinical diagnosis and forensic science
.
This round of financing will be mainly used for new technology exploration and product development
.
On August 3, Viterilon announced the completion of the B round of financing, raising a total of 200 million US dollars
.
This round of financing was led by Yunfeng Fund and Gaorong Capital.
After the completion of the financing, the company has raised a total of more than 300 million US dollars so far
.
According to the data, Vitarelon is committed to the development of innovative drugs for the treatment of aging-related degenerative diseases.
It plans to use the funds raised for the clinical development of receptor-interacting protein kinase 1 (RIPK1) inhibitors and further expand the company's research and development.
Scale and expand the R&D pipeline to develop various potential best-in-class/first-in-class drug candidates for aging-related degenerative diseases
.
On August 2, Taibang Bio announced that it has recently reached financing agreements with a number of investors and formally signed transaction documents
.
This round of financing totals US$300 million, led by Government Investment Corporation of Singapore (GIC) and Platinum Orchid, a wholly-owned subsidiary of Abu Dhabi Investment Authority (ADIA), with participation from China Life Equity and Cinda Kunpeng
.
In addition to the above-mentioned companies, a large number of companies such as tumor immunotherapy developer Yuanqi Bio, biopharmaceutical process development and large-scale production CDMO Zhixiang Bio, and clinical stage biopharmaceutical company Shuodi Bio have also recently completed billion-dollar investment and financing
.
On the whole, the number of financing events in the biomedical field is relatively large, and the financing scale is relatively large, involving a high degree of internationalization of investors
.
However, it should be noted that although the investment opportunities in the biopharmaceutical field are still favored by the industry as a whole, based on the uncertainty of the opening time of the next financing window, the industry also suggests that some companies can reduce costs and reduce costs.
Focus more on mature pipelines
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
